TuftsCSDD-Logo-Color.jpg
Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Clinical Trials, According to Tufts Center for the Study of Drug Development
May 04, 2021 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Increasing complexity of clinical trials targeting cancer—including use of more sophisticated scientific designs, larger global scope, and greater focus on...
TuftsCSDD-Logo-Color.jpg
Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines, According to Tufts Center for the Study of Drug Development
March 02, 2021 09:00 ET | Tufts Center for the Study of Drug Development
Tufts Center for the Study of Drug Development Analysis Finds Larger Pharmaceutical Companies Experience Longer Delays due to Mid-Study Updates BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Planned...
TuftsCSDD-Logo-Color.jpg
Rising Protocol Design Complexity Is Driving Rapid Growth in Clinical Trial Data Volume, According to Tufts Center for the Study of Drug Development
January 12, 2021 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ever more complex clinical trial designs are collecting much higher volumes of data from a variety of sources, intensifying pressure on drug sponsors to...
TuftsCSDD-Logo-Color.jpg
Kenneth I Kaitin to Retire from the Tufts Center for the Study of Drug Development after Leading the Organization for 23 Years
December 08, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Tufts Center for the Study of Drug Development (CSDD), the leading independent source of authoritative analyses on the nature and pace of pharmaceutical...
TuftsCSDD-Logo-Color.jpg
Transition to Decentralized Clinical Trials during the Coronavirus Pandemic Is far More Nuanced than Expected, According to Tufts Center for the Study of Drug Development
November 12, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The coronavirus pandemic has facilitated rapid adoption of decentralized clinical trial execution, with more than half of all global clinical trials now...
TuftsCSDD-Logo-Color.jpg
New Anti-infective Drugs Had a 14% Speed Advantage vs. Other Drugs During 2000-19, According to Tufts Center for the Study of Drug Development
September 15, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- New anti-infective drugs that won marketing approval in the United States during the last two decades took 14% less time to undergo clinical trials and...
TuftsCSDD-Logo-Color.jpg
MEDIA ADVISORY: Expert Commentary and Insight Available on COVID-19 Drug Development
August 06, 2020 09:00 ET | Tufts Center for the Study of Drug Development
Perspectives on COVID-19 Vaccine and Therapeutic Development from Tufts Center for the Study of Drug Development BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Experts from the Tufts Center for the...
TuftsCSDD-Logo-Color.jpg
Faster New Drug Approval Times Are More Than Offset by Longer Clinical Times in U.S., According to Tufts Center for the Study of Drug Development
July 16, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Although regulatory approval time for new drugs in the United States is shortening, the time needed, on average, to complete clinical development of those...
TuftsCSDD-Logo-Color.jpg
Tufts Center for the Study of Drug Development Establishes Demographic Benchmarks for Pivotal Clinical Trials, Showing Areas of Under-Representation
May 12, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Although up to 90% of pivotal clinical trials for drugs approved for sale in the United States provide data on study participants by sex, race, and age, less...
TuftsCSDD-Logo-Color.jpg
Drug Developers Are Responding to Evolving Data Demands with New Strategies and Tactics, According to Tufts Center for the Study of Drug Development
March 17, 2020 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, March 17, 2020 (GLOBE NEWSWIRE) -- Rapid growth in data volume and the diversity of data sources are leading drug developers to plan and adopt data management strategies and tactics to help...